Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an bisphosphonate, a potent inhibitor of bone resorption. It is indicated in the treatment of osteoporosis, Paget's disease of bone, bone metastases and malignant hypercalcemia. Intravenous administration.
At the date of last update we found no published data on its excretion in breast milk.
Most bisphosphonates are acidic compounds with low plasma concentrations. Both characteristics make it unlikely that they will be excreted in milk in clinically significant quantities.
Intestinal absorption of bisphosphonates is very low even on an empty stomach and is considered practically null in the presence of milk because they form unabsorbable compounds with calcium.
Some authors recommend monitoring the infant's serum calcium levels during maternal treatment. (Stathopoulos 2011)
Tiludronate and Zoledronate have the longest half-lives period of elimination and thus they are the less indicated to take while breastfeeding. Until more data on this drug in relation to breastfeeding are known safer alternatives are preferable (LactMed, French 2003, Siminoski 2000), especially in the neonatal period and in case of prematurity.
See below the information of these related products: